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Background: Inﬂammatory bowel disease (IBD) is linked to a
deﬁnite risk of thromboembolic events (TE), but data on the role of
prothrombotic genetic mutations are conﬂicting.
Study: Fourteen genetic factors involved in TE pathogenesis were
investigated in a homogeneous cohort of Sicilian patients with IBD
with and without history of TE and in healthy controls. Forty IBD
patients (21 CD, 19 UC) and 20 healthy individuals were enrolled.
Genetic testing was based on the reverse hybridization principle by
a commercial assay that analyzes 14 polymorphisms involved in
thrombophilia and cholesterol metabolism. The rate of genetic
polymorphisms and mutations was compared between IBD
patients and healthy controls.
Results: No signiﬁcant diﬀerence in allelic frequency was found
between IBD patients and controls except AGT T/T, though
a trend toward signiﬁcance was found also for ACE D/D. Eight
out of 9 patients with earlier history of TE had more than
1 polymorphism, compared with 12 out of 31 without TE. In
patients with IBD the mutation AGT T/T was related to male sex
(P<0.0259) and, marginally, to arterial hypertension (P<0.06)
and diabetes (P<0.09).
Conclusions: Our data conﬁrm a deﬁnite risk of TE in IBD (22.5%
of our series). An increased frequency of the genotypes ACE D/D
and AGT T/T, never reported so far, was found. In IBD patients
TE has a multifactorial genesis with involvement of several genes as
well and acquired factors. Genetic screening for prothrombotic
factors could help segregate IBD patients at higher risk of TE.
Key Words: thrombophilia, inﬂammatory bowel disease, genetic
mutations
(J Clin Gastroenterol 2011;45:e25–e29)
Ulcerative Colitis (UC) and Crohn’s disease (CD) areidiopathic inﬂammatory conditions of the bowel that
can involve organs other than the gastrointestinal tract. The
reported frequency of extraintestinal manifestations ranges
from 6% in a single population-based study1 to 47% in case
control studies.2,3 Vascular complications, mostly throm-
boembolic events (TE), have been described,1,4,5 and IBD
patients have a 3-fold risk of deep vein thrombosis and
pulmonary embolism as compared with the general
population.4,6 The reported frequency of TE in IBD varies
widely in the literature4,5 from 0.3% in clinical studies to
41% in autoptic studies. The annual incidence rate of
venous thromboembolism in both UC and CD was
approximately 0.5% in a population-based cohort of IBD
patients from Manitoba.6 Arterial TE have also been
reported7,8 and, more recently, CD has been associated to a
higher rate of cerebral arterial TE whereas an increased risk
of cardiac arterial TE was evidentiated in all IBD patients.9
TE are more frequent in young IBD patients and carry a
signiﬁcant risk of mortality.10 Many IBD patients with TE
have active disease or a recent history of major abdominal
surgery. By converse, a large study found that 77% of
peripheral venous thromboses occurred whereas the disease
was in clinical remission.4 It has hence been suggested
that IBD may be associated with a thrombotic tendency
independent from disease activity. Corticosteroids, often
used chronically in these patients because of steroid
dependency, can also induce a hypercoagulable state and
subsequently increase the thrombotic risk.11 Finally,
several autoptic studies had showed in CD patients
microthrombi located in blood vessels of the intestinal
mucosa,12 suggesting that vascular involvement could be
the ﬁrst pathogenetic step in the development of mucosal
damage.
Risk factors for thrombosis are classiﬁed as acquired
and genetic. Acquired risk factors, all frequent in IBD
patients, include inﬂammation, prolonged immobiliza-
tion or hospitalization, surgery, steroid therapy, ﬂuid
depletion, smoking, oral contraceptives, central venous
catheters, and hyperhomocysteinemia. The most com-
mon genetic prothrombotic factors are Factor V Leiden
(FVL), prothrombin G20210A mutations, and homo-
zygous C677T mutation in the methylenetetrahydrofolate
reductase (MTHFR).13 Over the last years, discrepant
results were reported on their role in TE in IBD
patients.10,14–30 Most studies found no signiﬁcant diﬀer-
ence in the rate of the above mentioned mutations
between IBD patients who developed TE and subjects
without IBD who experienced TE, but at least 2 reports
suggest an increased frequency of mutated alleles for
thrombophilia in IBD.21,31 Two more recent studies32,33
identiﬁed an increased expression of other candidate
genes for TE, oﬀering new clues for further research.
The aim of our study has been to investigate an
extended panel of genetic factors associated with pro-
thrombotic condition in a homogeneous cohort of Medi-
terranean IBD patients with and without TE compared
with a healthy control population.Copyright r 2011 by Lippincott Williams & Wilkins
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MATERIALS AND METHODS
Forty consecutive IBD patients followed up at the
Gastroenterology and Hepatology Unit of the University
Hospital of Palermo were enrolled between December 2007
and May 2008. UC and CD were diagnosed on classical
clinical, endoscopic, histological, and radiological criteria.
Twenty healthy individuals with personal and family
history negative for TE were used as healthy controls.
Information regarding age, sex, type of IBD, disease
localization, extraintestinal manifestations, disease dura-
tion and activity, therapy, earlier TE, familial predisposi-
tion for IBD and/or TE and risk factors for TE and/or
cardiovascular disease (smoking, hypertension, diabetes
mellitus, dyslipidemia, oral contraceptives, and hormone-
replacement therapy) were registered in a dedicated
database.
Fasting peripheral venous blood samples were col-
lected in vacutainer tubes that contained EDTA for
mutation analysis and for other blood tests (Hb, WBC,
PLT, ESR, CRP, total cholesterol, HDL-cholesterol,
ﬁbrinogen). They were stored at -201C until determination.
The following 14 gene polymorphisms were evaluated using
Cardio and Thrombo Test (Nuclear Laser Medicine srl,
Settala, Milano, Italy): 2 polymorphisms of Factor V
(Factor V R506Q and Factor V H1299R), 1 polymorphism
of Factor II (prothrombin G20210A), 2 polymorphisms of
methylenetetrahydrofolate reductase (MTHFR C677 T and
MTHFR A1298C), 1 polymorphism of cystathionine b
synthase (CBS T833C/844ins68), 1 polymorphism of
plasminogen activator inhibitor (PAI-1 4G/4G), 1 poly-
morphism of cholesterol ester transfer protein (CEPT
I405 V), 1 polymorphism of platelet glycoprotein IIIa
(GPIIIa T1565C), 1 polymorphism of cholesterol 7a-
hydroxylase (CYP7A1 A278C), 1 polymorphism of angio-
tensin-converting enzyme (ACE D/D), 2 polymorphisms of
genes encoding for apolipoproteins (ApoE T112C and
T158C), and 1 polymorphism for angiotensinogen (AGT
M235 T).
The test is based on the reverse hybridization principle
and includes 3 steps: (1) DNA is extracted from anti-
coagulated blood by a rapid procedure using 6100 PREP
STATION (Applied Biosystems, Monza, Milano, Italy), a
nucleic acids automatic puriﬁcation system; (2) relevant
gene sequences are simultaneously ampliﬁed by ‘‘real time’’
PCR and biotin-labelled; (3) ampliﬁcation products are
hybridized to a test strip which contains allele-speciﬁc
(wild-type and mutant) oligonucleotide probes as an array
of parallel lines. Bound biotinylated sequences are detected
using streptavidin-alkaline phosphatase and color sub-
strates.
Statistical analysis has been carried out using the
software Statistical Analysis System (SAS, Cary, NC).
Continuous variables are expressed as mean±standard
deviation, categorical variables as rate or percentage. Chi-
square test and Fisher exact test when necessary have been
used to compare genotypic distribution and allelic frequen-
cy. A diﬀerence was considered statistically signiﬁcant when
P<0.05.
RESULTS
Twenty-six women and 14 men were investigated;
mean age was 47.1 (SD±17.24) years. Twenty-one had CD
and nineteen had UC. Patients’ baseline features are given
in Table 1. Nine IBD patients (22.5%) had a history of TE
(Table 2). These patients had a mean age of 57.5 (SD±14)
years. Rates of genetic polymorphisms and mutations
are reported in Table 3. No signiﬁcant diﬀerence in allelic
frequency was found between IBD patients and controls
except AGT T/T, though a trend toward signiﬁcance
was found also for ACE D/D. No signiﬁcant diﬀerence
was observed between CD and UC patients. Eight out
of 9 patients with earlier history of TE had more than 1
polymorphism (Table 4), while in patients without TE
this is less frequent (12/31) and no more than 2
polymorphisms were observed. Smoking habits and contra-
ceptive consumption in IBD patients were not associated
with TE.
For the analysis of mutations of the ACE gene,
genotypes I/D and I/I were pooled and compared
with genotype D/D, whereas for the AGT gene geno-
types M/M and M/T were pooled and compared with
genotype T/T. In patients with IBD the mutation AGT T/T
was related with male sex (P<0.0259) and, marginally,
with arterial hypertension (P<0.06) and diabetes
(P<0.09).




Age (years, mean±SD) 47.1±17.24
CD/UC 21/9


















Previous thrombosis, n (%) 12 (30)
Smokers/ex, n (%) 14 (35)/5 (12.5)
Arterial hypertension, n (%) 12 (30)
Dyslipidemia, n (%) 5 (12.5)
Diabetes mellitus, n (%) 4 (10)
Oral contraceptives, n (%) 2 (5)
Hormone-replacement therapy, n (%) 4 (10)
Family history of IBD, n (%) 5 (12.5)
Family history of thrombosis, n (%) 8 (20)
Hemoglobin (g/dL) (mean±SD) 12.6±1.7
PLT (103/L) (mean±SD) 275±89.9
ESR (mm/h) (mean±SD) 19±19.7
CRP (mg/dL) (mean±SD) 2.1±2.9
Total cholesterol (mg/dL) (mean±SD) 172±62.4
HDL-cholesterol (mg/dL) (mean±SD) 48±18.5
Fibrinogen (mg/dL) (mean±SD) 360±97.6
CD indicates Crohn disease; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; IBD, inﬂammatory bowel disease; UC, ulcerative colitis.
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DISCUSSION
Research on the role of genetic prothrombotic factors
in IBD has led to conﬂicting results.10,14–30 Most studies
found no signiﬁcant diﬀerence in the rate of mutations
between IBD patients who developed TE and patients
without IBD who experienced TE, but at least 2 reports
suggest an increased frequency of mutated alleles for
thrombophilia in IBD.21,31 In the study by Liebman
et al,21 FVL mutation was found in 36% of 11 IBD
patients with history of TE versus 4% of 51 IBD
patients without history of TE. Similar results were
reached by Oldenburg et al.31
In the last 2 years, two more studies have addressed
this topic looking for expression of a larger panel of
polymorphisms. In particular, Koutroubakis et al32 identi-
ﬁed an increased expression of the alleles FV R506Q and
PAI-1 4G/4G in IBD while Yilmaz et al33 reported an
increased allelic frequency of X-Fibrinogen 455 G-A,
MTHFR A1298C and ACE I/D. These results suggest the
involvement of factors others than those commonly
associated with TE in subjects without IBD. The reason
for conﬂicting results could be due to the diﬀerent
characteristics of patients enrolled in previous studies in
terms of genetic background, ethnic origin, sample size, and
number of TE. Discrepant results could be explained also
by the diﬀerent mixing in various series of genetic and
acquired conditions predisposing to TE. Studies in the
Mediterranean area investigating the expression of the most
common genes associated with TE, that is FVL, MTHFR
mutations, and Factor II G20210A, did not ﬁnd associa-
tions with IBD.20,25,26,30 However, as suggested by other
studies, in IBD other candidate genes could act as triggers
for TE.32,33
Although the number of patients is small and the
number of TE events modest, our study accounts for a
consecutive, ethnically homogenous series of Sicilian
patients investigated using an extensive panel of 14 genes
associated with vascular events which, to our knowledge,
has never been assessed in this setting. In agreement with a
majority of studies, we were unable to show a diﬀerent
frequency of the most common genetic prothrombotic
factors (again FVL, MTHFR mutations and Factor II
G20210A) in patients with IBD with or without TE as
compared to controls. Nonetheless, we have demonstrated
the expression of multiple polymorphisms and mutations in
IBD patients with TE, a potentially relevant ﬁnding that
suggests that multiple genes may contribute to the
development and increased risk of TE. We also found an
increased frequency of AGT T/T, which has never been
reported so far in IBD, and, even if not statistically
signiﬁcant, of the genotypes ACE D/D, conﬁrming the
results of Yilmaz et al. These genes are more commonly
TABLE 2. Type of Vascular Complications in IBD Patients
Patients Thrombotic and Vascular Events
1 Carotid stenosis/Internal jugular vein thrombosis
2 Iliac arterial thrombosis
3 Deep vein thrombosis of the leg
4 Deep vein thrombosis of the leg/Iliac arterial thrombosis
5 Ischemic heart disease/Iliac arterial thrombosis
6 Common iliac vein thrombosis
7 Deep vein thrombosis of the leg
8 Deep vein thrombosis of the leg
9 Transient ischemic attack
IBD indicates inﬂammatory bowel disease.







Factor V R506Q (Leiden)
506 RR 38 (95) 19 (95)
506 RQ 2 (5) 1 (5) 0.455
506 QQ 0 0
Factor V H1299R
1299 HH 32 (80) 16 (80)
1299 HR 8 (20) 4 (20) 0.266
1299 RR 0 0
Prothrombin G20210A
20210 GG 40 (100) 19 (95)
20210 AG 0 1 (5) 0.333
20210 AA 0 0
MTHFR C677T
677 CC 13 (32.5) 5 (25)
677 CT 20 (50) 7 (35) 0.163
677 TT 7 (17.5) 8 (40)
MTHFR A1298C
1298 AA 19 (47.5) 10 (50)
1298 AC 15 (37.5) 9 (45) 0.509
1298 CC 6 (15) 1 (5)
CBS T833C/844ins68
CTR 36 (90) 16 (80) 0.173
CTR/INS 4 (10) 4 (20)
INS 0 0
PAI-1
4G/4G 5 (12.5) 7 (35)
4G/5G 23 (57.5) 8 (40) 0.117
5G/5G 12 (30) 5 (25)
CEPT I405V
I/I 17 (42.5) 7 (55)
I/V 21 (52.5) 12 (60) 0.85
V/V 2 (5) 1 (5)
GPIIIa T1565C
T/T 31 (77.5) 14 (70)
T/C 8 (20) 6 (30) 0.556
C/C 1 (2.5) 0
CYP7A1 A278C
A/A 12 (30) 4 (20)
A/C 19 (47.5) 12 (60) 0.624
C/C 9 (22.5) 4 (20)
ACE
D/D 20 (50) 11 (57.89)
I/D 17 (42.5) 7 (36.84) 0.075
I/I 3 (7.5) 1 (5.26)
APO E E2/E3/E4
E2/E2 0 1 (5)
E2/E3 4 (10) 0
E2/E4 1 (2.5) 0 0.375
E3/E3 29 (72.5) 17 (85)
E3/E4 5 (12.5) 2 (10)
E4/E4 1 (2.5) 0
AGT M235T
M/M 17 (42.5) 5 (25)
M/T 11 (27.5) 11 (55) 0.011
T/T 12 (30) 4 (20)
ACE indicates angiotensin-converting enzyme; AGT, angiotensinogen;
APO, apolipoproteins; CBS, cystathionine beta synthase; CEPT, cholesterol
ester transfer protein; CYP7A1, cholesterol 7a-hydroxylase; GPIIIa, platelet
glycoprotein IIIa; IBD, inﬂammatory bowel disease; MTHFR, methylene-
tetrahydrofolate reductase; PAI-1, plasminogen activator inhibitor-1.
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associated with arterial TE. ACE plays a role in platelet
activation and aggregation, while the AGT gene is linked
to early atherosclerosis, essential hypertension and atrial
ﬁbrillation.34,35 Indeed, early atherosclerosis is a clinical
feature common to several inﬂammatory and immuno-
logical diseases and a well-recognized marker of accelerated
atherogenesis, that is the intima-media thickness (IMT) of
the common carotid artery, has recently been detected in
patients with inﬂammatory bowel disease.36 Genetic poly-
morphisms of AGT and ACE predisposing to atherogenesis
could be crucial in determining mesenteric microvascular
thrombosis that many investigators believe to be a
contributing factor in the pathogenesis of IBD. In CD a
pathological angiogenesis could also play a critical role in
perpetuating and amplifying the inﬂammatory process.
These ﬁndings are in keeping with a recent epidemiology
study37 that found an increased rate of arterial vascular
complications in IBD.
Genetic proﬁling and identiﬁcation of acquired factors
could both help in stratifying patients at risk to choose the
best candidates for heparin prophylaxis thus minimizing
side eﬀects. Even if results of clinical trials, in which
anticoagulant drugs were used as the ﬁrst treatment for
IBD, have shown that they are safe,38 fear of hemorrhagic
complications is still a matter of concern among gastro-
enterologists worldwide. At the present time heparin is
recommended in hospitalized patients with IBD in general
by the American Society of Thromboembolism,39 while the
British Society of Gastroenterology40 recommends phar-
macological prophylaxis for TE only in hospitalized
patients with severe UC.
We suggest the use of genetic proﬁling for TE to
improve the selection of patients at risk in view also of the
potential clinical implications of the recent large retro-
spective study by Grainge et al41 which reports an even
higher risk of TE during ﬂares of IBD in nonhospitalized
patients, thus extending the indications to heparin prophy-
laxis.
In conclusion, our study focused on a comprehensive
evaluation of genetic factors related to thrombophilia in a
group of IBD patients with or without history of TE, and
found a possible role of two genes, ACE and AGT, which
needs, in consideration of the small sample size, to be
conﬁrmed in larger series and in multicentric studies.
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